Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2491 · SAFE Sunscreen Standards Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application

+14 −0Shown
More for 21 U.S.C. § 355h
Read § 355hOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 505G of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is amended by adding at the end the following:(r) Evidence and testing standards for active ingredients for topical administration.— (1) Evidence and testing standards for active ingredients for topical administration.— The Secretary shall— (A) in evaluating the generally recognized as safe and effective status of active …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 355h(r)–(r)

Start of § 355h to (r)(2)(A) unchanged ·

(B) Guidance Not later than 1 year after November 12, 2025, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.

(3) Clarification Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 321(p) of this title or the standards set forth under section 355 of this title for determining the safety and effectiveness of drugs.

(r) [inserted: Evidence and testing standards for active ingredients for topical administration.—]

(1) [inserted: Evidence and testing standards for active ingredients for topical administration.—] [inserted: The Secretary shall—]

(A) [inserted: in evaluating the generally recognized as safe and effective status of active ingredients used in nonprescription drugs intended for topical administration for purposes of subsection (a), utilize standards that allow for the use of real world evidence (as defined in section 505F(b)), as appropriate, as part of a comprehensive evaluation of scientific evidence to demonstrate the safety and effectiveness of such active ingredients, to supplement evidence from traditional clinical trials, provided that such standards allow the Secretary to evaluate whether the benefits of such active ingredients outweigh the risks; and]

(B) [inserted: apply subsection (b)(6)(C) to the regulation of active ingredients used in drugs intended for topical administration.]

(2) [inserted: Non-animal testing methods for topical active ingredients.—]

(A) [inserted: In general.—] [inserted: The Secretary shall consider the types of nonclinical tests described in paragraphs (1) through (4) of the first subsection (z) of section 505 (as inserted by section 3209(a)(2) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of Public Law 117–328)), or any other alternative to animal testing that the Secretary determines appropriate, in the consideration of drugs intended for topical administration under this section.]

(B) [inserted: Guidance.—] [inserted: Not later than 1 year after the date of enactment of this subsection, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.]

(3) [inserted: Clarification.—] [inserted: Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 201(p) or the standards set forth under section 505 for determining the safety and effectiveness of drugs.]

Step through the changes